BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

627 related articles for article (PubMed ID: 20664909)

  • 1. Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
    Konishi N; Hiroe K; Kawamura M
    Thromb Haemost; 2010 Sep; 104(3):504-13. PubMed ID: 20664909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.
    Kawamura M; Konishi N; Hiroe K; Shofuda K; Imaeda Y; Fujimoto T; Kubo K
    J Cardiovasc Pharmacol; 2010 Aug; 56(2):156-61. PubMed ID: 20410831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
    Pehrsson S; Johansson K; Kjaer M; Elg M
    Thromb Haemost; 2010 Dec; 104(6):1242-9. PubMed ID: 20806126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
    Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
    Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models.
    Furugohri T; Shiozaki Y; Muramatsu S; Honda Y; Matsumoto C; Isobe K; Sugiyama N
    Eur J Pharmacol; 2005 May; 514(1):35-42. PubMed ID: 15878322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of action of the oral direct thrombin inhibitor ximelagatran.
    Mattsson C; Sarich TC; Carlsson SC
    Semin Vasc Med; 2005 Aug; 5(3):235-44. PubMed ID: 16123910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotic and anticoagulant effects of direct factor Xa inhibitor darexaban in rat and rabbit models of venous thrombosis.
    Kaku S; Uemura T; Saitoh M; Suzuki K; Iwatsuki Y; Funatsu T; Kawasaki T
    Eur J Pharmacol; 2013 Jan; 699(1-3):40-7. PubMed ID: 23200896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma.
    Boström SL; Hansson GF; Sarich TC; Wolzt M
    Thromb Res; 2004; 113(1):85-91. PubMed ID: 15081569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HD1, a thrombin- and prothrombin-binding DNA aptamer, inhibits thrombin generation by attenuating prothrombin activation and thrombin feedback reactions.
    Kretz CA; Cuddy KK; Stafford AR; Fredenburgh JC; Roberts R; Weitz JI
    Thromb Haemost; 2010 Jan; 103(1):83-93. PubMed ID: 20062917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combination of a thrombin inhibitor and dexamethasone prevents the development of experimental disseminated intravascular coagulation in rats.
    Elg M; Gustafsson D
    Thromb Res; 2006; 117(4):429-37. PubMed ID: 15869787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
    Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
    Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paradoxical enhancement of the intrinsic pathway-induced thrombin generation in human plasma by melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, or heparin.
    Furugohri T; Morishima Y
    Thromb Res; 2015 Sep; 136(3):658-62. PubMed ID: 26188924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects.
    Sarich TC; Eriksson UG; Mattsson C; Wolzt M; Frison L; Fager G; Gustafsson D
    Thromb Haemost; 2002 Feb; 87(2):300-5. PubMed ID: 11858491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery.
    Weitz JI; Cao C; Eriksson BI; Fisher W; Kupfer S; Raskob G; Spaeder J; Turpie AG
    Thromb Haemost; 2010 Dec; 104(6):1150-7. PubMed ID: 20886185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulant action of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in umbilical cord and adult plasma: an in vitro examination.
    Koestenberger M; Gallistl S; Cvirn G; Baier K; Leschnik B; Muntean W
    Thromb Res; 2005; 115(1-2):135-42. PubMed ID: 15567465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.
    Schulman S; Wåhlander K; Lundström T; Clason SB; Eriksson H;
    N Engl J Med; 2003 Oct; 349(18):1713-21. PubMed ID: 14585939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
    Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR
    Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
    Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
    Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The oral direct thrombin inhibitor, ximelagatran, an alternative for anticoagulant treatment during the puerperium and lactation.
    Hellgren M; Johansson S; Eriksson UG; Wåhlander K
    BJOG; 2005 May; 112(5):579-83. PubMed ID: 15842280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.